News

Applied Clinical Trials Online2d
Otsuka’s Sibeprenlimab Demonstrates Meaningful Outcomes in Phase III Study for Immunoglobulin A Nephropathy
In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...
Newseria BIZNES4d
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Gains Momentum with Next-Gen Therapies | CI Insights
As CIDP moves toward targeted therapies and patient-friendly regimens, the market is primed for disruption—offering a fresh ...